Alnylam Pharmaceuticals, Inc. (ALNY) — Analyst outlook / Analyst consensus target is. Based on 52 analyst ratings, the consensus is bullish — 39 Buy, 12 Hold, 1 Sell.
The consensus price target is $460.50 (low: $351.00, high: $549.00), representing an upside of 35.7% from the current price $339.41.
Analysts estimate Earnings Per Share (EPS) of $-2.06 and revenue of $2.24B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.16 vs est $-2.06 (missed -4.8%). 2025: actual $2.39 vs est $2.46 (missed -3%). Analyst accuracy: 96%.
ALNY Stock — 12-Month Price Forecast
$460.50
▲ +35.68% Upside
Average Price Target
Based on 52 Wall Street analysts offering 12-month price targets for Alnylam Pharmaceuticals, Inc., the average price target is $460.50, with a high forecast of $549.00, and a low forecast of $351.00.
The average price target represents a +35.68% change from the last price of $339.41.
Highest Price Target
$549.00
Average Price Target
$460.50
Lowest Price Target
$351.00
ALNY Analyst Ratings
Buy
Based on 52 analysts giving stock ratings to Alnylam Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — ALNY
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.16
vs Est –$2.06
▼ 4.6% off
2025
Actual $2.39
vs Est $2.46
▼ 3.1% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — ALNY
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $2.248B
vs Est $2.243B
▲ 0.2% off
2025
Actual $3.714B
vs Est $3.751B
▼ 1.0% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
